170 Harbor Way P.O. Box 511 South San Francisco, CA 94083
Phone: 650-837-7000 www.exelixis.com

George Scangos, president and CEO NASDAQ:EXEL


Exelixis Inc. is a biotechnology company focused on product development for the life sciences industries through its expertise in comparative genomics and model system genetics. Exelixis has developed broad-based capabilities in bioinformatics, genomics, proteomics and biochemical technologies, resulting in a platform that permits scientists to answer disease-based questions in a systematic manner.

After a functional target or pathway is discovered in a simple organism, an integrated suite of proprietary comparative genomics tools is used to identify the corresponding gene or pathway of interest in humans, plants or livestock. This target identification program is used to select and validate novel targets that will lead to new pharmaceuticals in the areas of cancer, angiogenesis, inflammation, the central nervous system and metabolism.

In its Mechanism of Action program, Exelixis identifies the molecular targets and biochemical pathways of existing pharmaceutical and agrochemical compounds, in a reverse compound-to-target approach.

Exelixis in April 2001 acquired Artemis Pharmaceuticals GmbH, headquartered in Cologne, Germany. In December 2000, Exelixis acquired Agritope Inc., of Portland, Ore., expanding its model system approach for novel therapeutic discovery to the arena of plant biology. Agritope was renamed Exelixis Plant Sciences Inc., a wholly owned subsidiary. In January 2000, Exelixis and Bayer AG, of Leverkusen, Germany, expanded their initial relationship with the creation of a South San Francisco joint venture called Genoptera LLC, which aims to discover new generations of insecticides and nematicides.


Jointly design a custom high-throughput screening compound library to use in their respective high-throughput screening efforts: Scios Inc.

Generation of a custom high-throughput screening compound library for use by both parties: Elan Pharmaceuticals Inc.

Broad collaboration and licensing agreement to create a new generation of cancer drugs: Bristol-Myers Squibb Co.

Discovery and development of humanized antibodies for the diagnosis, prevention and treatment of cancer: Protein Design Labs Inc.

Strategic alliance for antisense drug discovery research and development in order to define gene function in vivo on a genome-wide scale in zebrafish and other model organisms: AVI BioPharma Inc.

Development of novel fungicides and herbicides for crop protection: Dow AgroSciences LLC.

Exelixis has also partnered with Sangamo BioSciences Inc., Artemis Pharmaceuticals GmbH, Dow AgroSciences, Pharmacia Corp. and Bayer AG..

In addition to research, discovery and product development-specific collaborations, Exelixis has collaborations with biotechnology product developers and solution providers, including Affymetrix Inc., Agilent Technologies Inc. and Orchid BioSciences Inc. In addition, the company maintains active collaborations with several universities and academic institutions.